TRH

Thyrotropin-releasing Hormone (Protirelin)

Evidence & Status

  • Strong Human Evidence
  • Established

At a Glance

The smallest known hypothalamic releasing hormone, which regulates thyroid function through the pituitary. Its injectable diagnostic form (protirelin/Thyrel) was FDA-approved but is now discontinued. Proposed direct CNS effects — wakefulness, antidepressant activity, neuroprotection — remain mostly preclinical.

Plain English

Researchers study TRH (Thyrotropin-Releasing Hormone) because, despite being a very small molecule, it has a well-established role regulating thyroid function and some intriguing preclinical effects in the nervous system beyond that role. An injectable form (protirelin) was once FDA-approved as a diagnostic test for thyroid function, though it's since been discontinued as newer tests took over. Scientists remain interested in its potential direct brain effects — including wakefulness promotion and neuroprotection — but this research is still largely at the animal-study stage, and claims about human antidepressant benefits have not been independently verified.

Overview

The smallest known hypophysiotropic releasing hormone, produced in hypothalamic paraventricular neurons. Its N-terminal residue is pyroglutamate (pGlu) — an intramolecularly cyclized glutamine/glutamate residue, not a head-to-tail cyclic (macrocyclic) tripeptide. TRH classically stimulates pituitary TSH and prolactin release to regulate the thyroid axis. A historical pharmacokinetic study in 16 euthyroid subjects (IV, intranasal, and oral protirelin) found rapid IV clearance (half-life ≈6.5 minutes) with a TSH peak roughly 30 minutes after the TRH peak (Duntas et al., 1988). Protirelin (Thyrel TRH) was an FDA-approved injectable diagnostic product (NDA 018087); FDA currently lists it as discontinued. Direct CNS effects independent of the thyroid axis — analeptic activity, antidepressant-like effects, and neuroprotection in spinal cord injury and ALS models — are supported mainly by preclinical and mechanistic research; human intranasal-depression evidence was not independently verified in this review and related claims have been removed.

Research Summary

TRH is a well-characterized hypothalamic hormone: its pharmacokinetics in humans (IV, intranasal, and oral administration) were established in a 1988 study, and its endocrine pharmacology (TSH/prolactin stimulation) is textbook physiology. Protirelin (Thyrel TRH) was an FDA-approved injectable diagnostic product for thyroid function testing, now discontinued per current FDA records. Two registered clinical trials (NCT00054756, NCT00790296) further document TRH's investigation in diagnostic and physiological contexts; no efficacy outcome data from either was independently verified in this review. TRH's proposed CNS effects independent of the thyroid axis — wakefulness promotion, antidepressant-like activity, and neuroprotection in spinal cord injury/ALS models — remain preclinical or mechanistic; no independently verified human evidence for an intranasal-depression benefit was identified, and that claim has been removed rather than carried forward.

Research Areas

  • Thyroid axis regulation
  • CNS analeptic effects
  • Antidepressant mechanisms
  • Spinal cord injury neuroprotection
  • ALS research

Safety & Risks

Serious Risks

  • Cardiovascular effects with rapid IV administration
  • Transient TSH and prolactin elevation following administration
  • Pituitary overstimulation in susceptible individuals

Reported Side Effects

  • Nausea
  • Urge to urinate
  • Flushing
  • Metallic taste
  • Mild tachycardia
  • Increased prolactin
United States
Protirelin (Thyrel TRH, NDA 018087) was an FDA-approved injectable diagnostic product; FDA currently lists it as discontinued. Native/endogenous TRH itself does not have a current FDA-approved drug-product context.
United Kingdom
Research use only; no verified current regulatory approval identified
Australia
Research use only; no verified current regulatory approval identified
Canada
Research use only; no verified current regulatory approval identified

Citations & Sources